Literature DB >> 19009722

Hip fracture and proton pump inhibitor therapy: position statement.

Paul Moayyedi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19009722      PMCID： PMC2661308          DOI： 10.1155/2008/284165

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN： 0835-7900            Impact factor:   3.522


× No keyword cloud information.
  8 in total

Review 1.  Proton pump-inhibiting drugs, calcium homeostasis, and bone health.

Authors:  Matthew J Wright; Deborah D Proctor; Karl L Insogna; Jane E Kerstetter
Journal:  Nutr Rev       Date:  2008-02       Impact factor: 7.110

2.  Proton pump inhibitors: balancing the benefits and potential fracture risks.

Authors:  J Brent Richards; David Goltzman
Journal:  CMAJ       Date:  2008-08-12       Impact factor: 8.262

3.  Long-term proton pump inhibitor therapy and risk of hip fracture.

Authors:  Yu-Xiao Yang; James D Lewis; Solomon Epstein; David C Metz
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

4.  Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro.

Authors:  J Tuukkanen; H K Väänänen
Journal:  Calcif Tissue Int       Date:  1986-02       Impact factor: 4.333

5.  Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Calcif Tissue Int       Date:  2006-08-15       Impact factor: 4.333

Review 6.  Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm.

Authors:  Paul Moayyedi; Ann Cranney
Journal:  Am J Gastroenterol       Date:  2008-10       Impact factor: 10.864

7.  Use of proton pump inhibitors and risk of osteoporosis-related fractures.

Authors:  Laura E Targownik; Lisa M Lix; Colleen J Metge; Heather J Prior; Stella Leung; William D Leslie
Journal:  CMAJ       Date:  2008-08-12       Impact factor: 8.262

8.  Warfarin therapy and risk of hip fracture among elderly patients.

Authors:  Muhammad Mamdani; Ross E G Upshur; Geoff Anderson; Bill R Bartle; Andreas Laupacis
Journal:  Pharmacotherapy       Date:  2003-01       Impact factor: 4.705
  8 in total
  5 in total

Review 1.  The risks of PPI therapy.

Authors:  Paul Moayyedi; Grigorios I Leontiadis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 46.802

2.  The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  Laura E Targownik; William D Leslie; K Shawn Davison; David Goltzman; Sophie A Jamal; Nancy Kreiger; Robert G Josse; Stephanie M Kaiser; Christopher S Kovacs; Jerilynn C Prior; Wei Zhou
Journal:  Am J Gastroenterol       Date:  2012-07-10       Impact factor: 10.864

Review 3.  Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2010-12

4.  Proton Pump Inhibitors and Dementia: Deciphering the Data.

Authors:  Paul Moayyedi; Maxine A Lewis
Journal:  Am J Gastroenterol       Date:  2017-12       Impact factor: 10.864

5.  Proton pump inhibitors and risk of bone fractures.

Authors:  Grigorios I Leontiadis; Paul Moayyedi
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.